Segmental bowel resection combined with the DEP regimen
Segmental bowel resection combined with the DEP regimen: Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Study summary
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Met HLH-2004 diagnostic criteria;
* EBV-DNA in the peripheral blood \> 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues;
* Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;
* Age \>18 years old, gender is not limited;
* Estimated survival time \> 1 month;
* Informed consent obtained.
Exclusion Criteria:
* Active infections (viral, bacterial, fungal or parasitic);
* Diagosed with malignant tumos within 5 years;
* Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;
* Heart function above grade II (NYHA);
* Severe myocardial injury:TNT、TNI、CK-MB \> 3 ULN;
* Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease;
* Pregnancy or lactating Women;
* Allergic to pegylated liposomal doxorubicin and etoposide;
* HIV antibody positivity;
* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);
* Participate in other clinical research at the same time;
* The researchers considered that patients are not suitable for the study.
Primary outcome measure(s)
ORR — 4 Week The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.
Adverse events — 1 month Incidence of adverse reactions
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.